RedHill's Yeliva yields one partial response in MM patient in preliminary Phase Ib data

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said Yeliva opaganib (ABC294640) led to one very good partial response and two cases of stable disease lasting more than four months among 10 evaluable multiple myeloma patients in the Phase Ib portion of a Phase Ib/II trial. Data were presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Dublin.

No dose-limiting toxicities (DLTs) were observed and the most common adverse events were nausea, vomiting and fatigue...